About the Company
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ETTX News
Sofinnova Venture Partners IX, L.P.'s Net Worth
This is based on reported shares across multiple companies, which include Entasis Therapeutics Holdings Inc., Iterum Therapeutics plc, Checkmate Pharmaceuticals, Inc., Galera Therapeutics ...
Patrick J Heron's Net Worth
Who is Patrick J Heron? Patrick J Heron has an estimated net worth of $804 Million. This is based on reported shares across multiple companies, which include Vaxcyte, Inc., Trubion Pharmaceuticals ...
CERo Therapeutics Holdings Inc CERO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...
RANI Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States.
Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
ME THERAPEUTICS HOLDINGS INC
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting ...
ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver ...
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript March 20, 2024 Rani Therapeutics Holdings, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations ...
Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...
Arcturus Therapeutics Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...